# OnCo record nct03699475 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03699475/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03699475", "NCT03699475" ;
  schema:name "Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS"@en ;
  schema:description "A phase 2/3 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated."@en ;
  schema:url <https://onco.cc/trials/nct03699475/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03699475> ;
  onco:status "historic" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:drugs <https://onco.cc/drugs/rivogenlecleucel/> ;
  onco:companies <https://onco.cc/companies/bellicum/> .